Live
- ‘Gully Gang Stars’ review: A gripping tale of resilience and justice
- Train crew suspended for violating speed limit
- Scrap NITI Aayog, bring back Planning Commission: Mamata
- Know your MLA: Satya Prabha continues husband’s legacy with resounding victory
- Dharani Revamp on Cards: CM calls for in-depth study to resolve Dharani lapses
- Huge scam in government ads
- NITI Aayog to focus on ‘Viksit Bharat @2047’
- PM playing petty politics: Oppn
- Jagan government destroyed AP economy says Chandrababu Naidu
- On Kargil Vijay Diwas, Modi hails Agnipath, targets Opposition
Just In
Lippo-backed Venturra Capital and Prenetics to Bring Personalized Medicine to Indonesia
![](/images/authorplaceholder.jpg?type=1&v=2)
![Lippo-backed Venturra Capital and Prenetics to Bring Personalized Medicine to Indonesia Lippo-backed Venturra Capital and Prenetics to Bring Personalized Medicine to Indonesia](https://assets.thehansindia.com/hansindia-bucket/5832_Venture capital.jpg)
The Lippo Group, one of the largest conglomerates and the biggest healthcare provider in Indonesia, through it\'s affiliate Venturra Capital, signed a Memordandum of Understanding (MoU) with Preneticsâ„¢, a Personalized & Precision Medicine Life Sciences company based in Hong Kong. Under the terms of the MoU, Venturra Capital will invest an un-disclosed amount in the USD millions into Prenetics.
The Lippo Group, one of the largest conglomerates and the biggest healthcare provider in Indonesia, through it's affiliate Venturra Capital, signed a Memordandum of Understanding (MoU) with Prenetics™, a Personalized & Precision Medicine Life Sciences company based in Hong Kong. Under the terms of the MoU, Venturra Capital will invest an un-disclosed amount in the USD millions into Prenetics.
In addition, the Lippo Group will act as a strategic partner for an initial period of 5-Years to offer personalized & precision medicine in Indonesia. Prenetics has developed its proprietary iGenes Pharmacogenomics test. Pharmacogenomics is the study of how genes affects a person's response to drugs. iGenes is a non-invasive, saliva based test with a report ready to physicians within 48 hours. The iGenes report will identify the right drug, at the right dosage, tailored to a patient's genetic make-up.
$213 billion in avoidable and unnecessary healthcare costs, affects millions of people (USA)Prenetics also Announces World-Class Scientific, Medical and Commercial Advisory Board
![](/images/logo.png)
© 2024 Hyderabad Media House Limited/The Hans India. All rights reserved. Powered by hocalwire.com